We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abcam

Abcam is an innovator in reagents and tools, and provides tools and scientific support to the research and clinical c... read more Featured Products: More products

Download Mobile App




Danaher Acquires UK Biotech Company Abcam

By LabMedica International staff writers
Posted on 30 Aug 2023
Print article
Image: Abcam is expected to brand within Danaher’s Life Sciences segment (Photo courtesy of Abcam)
Image: Abcam is expected to brand within Danaher’s Life Sciences segment (Photo courtesy of Abcam)

Danaher Corporation (Waltham, MA, USA) has entered into a definitive agreement to acquire all of the outstanding shares of Abcam plc (Cambridge, UK) for USD 24 per share in cash. The transaction was unanimously approved and recommended by the Abcam board of directors and unanimously approved by the Danaher board of directors.

Founded in 1998, Abcam offers the scientific community a wide range of extensively validated antibodies, reagents, biomarkers, and assays. These resources serve to target key biological pathways critical for the advancement of drug discovery, life sciences research, and diagnostics. The company's technologies find application among approximately 750,000 researchers. Under the planned arrangement, Abcam is poised to continue operating as an independent entity and brand within Danaher's Life Sciences sector. The acquisition of Abcam reflects Danaher's strategy to contribute towards mapping complex diseases and accelerating the process of drug discovery.

“Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community,” said Alan Hirzel, Chief Executive Officer of Abcam. “Danaher shares our passion to help life science researchers achieve their mission faster and their operating company model allows us to continue to pursue our strategy, while harnessing the power of the Danaher Business System to ensure we remain the partner of choice for our customers.”

“We couldn’t be more excited to have Abcam join Danaher,” added Rainer M. Blair, President and Chief Executive Officer, Danaher. “Abcam’s long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam’s innovative and talented team to Danaher as we continue to help our customers solve some of the world’s biggest healthcare challenges."

Related Links:
Danaher Corporation 
Abcam plc

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.